BPC-157 in Clinical Trials for IBD: Comprehensive Animal Evidence Supporting Human Testing
BPC-157 (PL-10, PLD-116, PL 14736) in IBD clinical trials is supported by comprehensive animal evidence: healing across multiple gut inflammation models, cytoprotection, anti-inflammation, and NO/prostaglandin modulation.
Quick Facts
What This Study Found
BPC-157 (Pliva clinical trial designations: PL-10, PLD-116, PL 14736) for IBD is supported by extensive animal data: heals colitis/esophagitis/gastric lesions, provides cytoprotection, reduces inflammation through NO and prostaglandin pathways, and maintains gut integrity across multiple models.
Key Numbers
How They Did This
animal-study study on bpc-157, gut-healing.
Why This Research Matters
Relevant for bpc-157, gut-healing.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding BPC-157 (Pliva clinical trial designations: PL-10, PLD-116, PL 14736) for IBD is supported by extensive animal data: heals colitis/esophagitis/gastric
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2006.
- Original Title:
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.
- Published In:
- Inflammopharmacology, 14(5-6), 214-21 (2006)
- Authors:
- Sikiric, P(36), Seiwerth, S(42), Brcic, L(6), Blagaic, A B, Zoricic, I, Sever, M, Klicek, R, Radic, B, Keller, N, Sipos, K, Jakir, A, Udovicic, M, Tonkic, A, Kokic, N, Turkovic, B, Mise, S, Anic, T
- Database ID:
- RPEP-01187
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
BPC-157 in Clinical Trials for IBD: Comprehensive Animal Evidence Supporting Human Testing
What was found?
BPC-157 (PL-10, PLD-116, PL 14736) in IBD clinical trials is supported by comprehensive animal evidence: healing across multiple gut inflammation models, cytoprotection, anti-inflammation, and NO/prostaglandin modulation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01187APA
Sikiric, P; Seiwerth, S; Brcic, L; Blagaic, A B; Zoricic, I; Sever, M; Klicek, R; Radic, B; Keller, N; Sipos, K; Jakir, A; Udovicic, M; Tonkic, A; Kokic, N; Turkovic, B; Mise, S; Anic, T. (2006). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.. Inflammopharmacology, 14(5-6), 214-21.
MLA
Sikiric, P, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.." Inflammopharmacology, 2006.
RethinkPeptides
RethinkPeptides Research Database. "Stable gastric pentadecapeptide BPC 157 in trials for inflam..." RPEP-01187. Retrieved from https://rethinkpeptides.com/research/sikiric-2006-stable-gastric-pentadecapeptide-bpc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.